A Nitrobenzoyl Sesquiterpenoid Insulicolide A Prevents Osteoclast Formation Suppressing C-Fos-NFATc1 Signaling Pathway

Overview

Journal Front Pharmacol

Date 2022 Feb 3

PMID 35111044

Authors

Yanhui Tan

Minhong Ke

Zhichao Li

Yan Chen

Jiehuang Zheng

Yiyuan Wang

Xuefeng Zhou

Gang Huang

Xiaojuan Li

Affiliations

Soon will be listed here.

Abstract

It is a viable strategy to inhibit osteoclast differentiation for the treatment of osteolytic diseases such as osteoporosis, rheumatoid arthritis and tumor bone metastases. Here we assessed the effects of insulicolide A, a natural nitrobenzoyl sesquiterpenoid derived from marine fungus, on receptor activator of nuclear factor-κB ligand (RANKL)-stimulated osteoclastogenesis and its protective effects on LPS-induced osteolysis mice model . The results demonstrated that insulicolide A inhibited osteoclastogenesis from 1 μM . Insulicolide A could prevent c-Fos and nuclear factor of activated T-cell cytoplasmic 1 (NFATc1) nuclear translocation and attenuate the expression levels of osteoclast-related genes and DC-STAMP during RANKL-stimulated osteoclastogenesis but have no effects on NF-κB and MAPKs. Insulicolide A can also protect the mice from LPS-induced osteolysis. Our research provides the first evidence that insulicolide A may inhibit osteoclastogenesis both and , and indicates that it may have potential for the treatment of osteoclast-related diseases.

Citing Articles

Plant molecules reinforce bone repair: Novel insights into phenol-modified bone tissue engineering scaffolds for the treatment of bone defects.

Chen Y, Gan W, Cheng Z, Zhang A, Shi P, Zhang Y Mater Today Bio. 2024; 24:100920.

PMID: 38226013 PMC: 10788623. DOI: 10.1016/j.mtbio.2023.100920.

CGK733 alleviates ovariectomy-induced bone loss through blocking RANKL-mediated Ca oscillations and NF-κB/MAPK signaling pathways.

Xu M, Song D, Xie X, Qin Y, Huang J, Wang C iScience. 2023; 26(10):107760.

PMID: 37720109 PMC: 10504545. DOI: 10.1016/j.isci.2023.107760.

Nano-Based Co-Delivery System for Treatment of Rheumatoid Arthritis.

Zhang S, Zhang M, Li X, Li G, Yang B, Lu X Molecules. 2022; 27(18).

PMID: 36144709 PMC: 9503141. DOI: 10.3390/molecules27185973.

References

Stickeler E, Fehm T . Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?. Breast Care (Basel). 2014; 9(3):161-7. PMC: 4132236. DOI: 10.1159/000365129. View

Kang H, Seo C, Park Y . The effects of marine carbohydrates and glycosylated compounds on human health. Int J Mol Sci. 2015; 16(3):6018-56. PMC: 4394518. DOI: 10.3390/ijms16036018. View

Li X, Udagawa N, Takami M, Sato N, Kobayashi Y, Takahashi N . p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology. 2003; 144(11):4999-5005. DOI: 10.1210/en.2003-0166. View

Wada T, Nakashima T, Hiroshi N, Penninger J . RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2005; 12(1):17-25. DOI: 10.1016/j.molmed.2005.11.007. View

Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M . Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem. 2000; 275(40):31155-61. DOI: 10.1074/jbc.M001229200. View

Lorenzo J . The many ways of osteoclast activation. J Clin Invest. 2017; 127(7):2530-2532. PMC: 5490742. DOI: 10.1172/JCI94606. View

Ghosh S, Karin M . Missing pieces in the NF-kappaB puzzle. Cell. 2002; 109 Suppl:S81-96. DOI: 10.1016/s0092-8674(02)00703-1. View

Tanaka S, Nakamura K, Takahasi N, Suda T . Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005; 208:30-49. DOI: 10.1111/j.0105-2896.2005.00327.x. View

Nepal M, Choi H, Choi B, Yang M, Chae J, Li L . Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways. Eur J Pharmacol. 2013; 715(1-3):96-104. DOI: 10.1016/j.ejphar.2013.06.002. View

10.

Wu Q, Jin X, Draskovic M, Crews M, Tenney K, Valeriote F . Unraveling the Numerous Biosynthetic Products of the Marine Sediment-Derived Fungus, Aspergillus insulicola. Phytochem Lett. 2012; 5(1):114-117. PMC: 3285095. DOI: 10.1016/j.phytol.2011.11.005. View

11.

Jimi E, Ghosh S . Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev. 2005; 208:80-7. DOI: 10.1111/j.0105-2896.2005.00329.x. View

12.

Cappellen D, Luong-Nguyen N, Bongiovanni S, Grenet O, Wanke C, Susa M . Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem. 2002; 277(24):21971-82. DOI: 10.1074/jbc.M200434200. View

13.

Chiu Y, Ritchlin C . DC-STAMP: A Key Regulator in Osteoclast Differentiation. J Cell Physiol. 2016; 231(11):2402-7. PMC: 4946985. DOI: 10.1002/jcp.25389. View

14.

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

15.

Broadhead M, Clark J, Dass C, Choong P, Myers D . Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets. 2011; 15(2):169-81. DOI: 10.1517/14728222.2011.546351. View

16.

Place D, Malireddi R, Kim J, Vogel P, Yamamoto M, Kanneganti T . Osteoclast fusion and bone loss are restricted by interferon inducible guanylate binding proteins. Nat Commun. 2021; 12(1):496. PMC: 7820603. DOI: 10.1038/s41467-020-20807-8. View

17.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

18.

Tan Y, Deng W, Zhang Y, Ke M, Zou B, Luo X . A marine fungus-derived nitrobenzoyl sesquiterpenoid suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and inflammatory bone destruction. Br J Pharmacol. 2020; 177(18):4242-4260. PMC: 7443469. DOI: 10.1111/bph.15179. View

19.

Liu Y, Liu W, Yu Z, Zhang Y, Li Y, Xie D . A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways. Cell Death Dis. 2021; 12(7):654. PMC: 8236062. DOI: 10.1038/s41419-021-03939-7. View

20.

Edwards J, Mundy G . Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol. 2011; 7(4):235-43. DOI: 10.1038/nrrheum.2011.23. View